Abbott Laboratories $ABT is Wendell David Associates Inc.’s 9th Largest Position

Wendell David Associates Inc. cut its holdings in Abbott Laboratories (NYSE:ABT) by 3.0% in the fourth quarter, according to the company in its most recent disclosure with the SEC. The fund owned 211,692 shares of the healthcare product maker’s stock after selling 6,511 shares during the quarter. Abbott Laboratories comprises 2.7% of Wendell David Associates Inc.’s holdings, making the stock its 9th largest position. Wendell David Associates Inc.’s holdings in Abbott Laboratories were worth $26,523,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. Harbor Capital Advisors Inc. purchased a new stake in Abbott Laboratories in the fourth quarter valued at about $27,000. Cloud Capital Management LLC purchased a new stake in Abbott Laboratories in the third quarter valued at about $29,000. Guerra Advisors Inc purchased a new stake in Abbott Laboratories in the third quarter valued at about $31,000. Bridge Generations Wealth Management LLC purchased a new stake in Abbott Laboratories in the third quarter valued at about $33,000. Finally, Copia Wealth Management purchased a new stake in Abbott Laboratories in the third quarter valued at about $38,000. 75.18% of the stock is currently owned by hedge funds and other institutional investors.

Abbott Laboratories Stock Down 2.5%

Abbott Laboratories stock opened at $91.52 on Thursday. The firm has a market cap of $159.40 billion, a price-to-earnings ratio of 25.64, a price-to-earnings-growth ratio of 1.55 and a beta of 0.79. Abbott Laboratories has a 52 week low of $90.72 and a 52 week high of $139.06. The business’s 50-day moving average price is $104.76 and its 200 day moving average price is $116.38. The company has a quick ratio of 1.18, a current ratio of 1.58 and a debt-to-equity ratio of 0.19.

Abbott Laboratories (NYSE:ABT) last posted its earnings results on Thursday, April 16th. The healthcare product maker reported $1.15 EPS for the quarter, topping the consensus estimate of $1.14 by $0.01. The firm had revenue of $11.16 billion for the quarter, compared to analyst estimates of $10.99 billion. Abbott Laboratories had a return on equity of 17.71% and a net margin of 13.90%.Abbott Laboratories’s revenue for the quarter was up 7.8% compared to the same quarter last year. During the same period last year, the company earned $1.09 earnings per share. Abbott Laboratories has set its FY 2026 guidance at 5.380-5.580 EPS and its Q2 2026 guidance at 1.250-1.310 EPS. As a group, sell-side analysts anticipate that Abbott Laboratories will post 5.48 earnings per share for the current year.

Abbott Laboratories Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Friday, May 15th. Shareholders of record on Wednesday, April 15th will be issued a $0.63 dividend. This represents a $2.52 annualized dividend and a yield of 2.8%. The ex-dividend date of this dividend is Wednesday, April 15th. Abbott Laboratories’s dividend payout ratio (DPR) is presently 70.59%.

Insider Buying and Selling

In other Abbott Laboratories news, CFO Philip P. Boudreau acquired 2,200 shares of the company’s stock in a transaction on Thursday, April 23rd. The shares were bought at an average cost of $91.50 per share, with a total value of $201,300.00. Following the completion of the acquisition, the chief financial officer owned 2,200 shares in the company, valued at approximately $201,300. This trade represents a ∞ increase in their ownership of the stock. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, Director Daniel J. Starks acquired 10,000 shares of the company’s stock in a transaction on Monday, April 27th. The stock was acquired at an average cost of $92.65 per share, for a total transaction of $926,500.00. Following the completion of the acquisition, the director owned 6,751,103 shares of the company’s stock, valued at $625,489,692.95. This trade represents a 0.15% increase in their position. Additional details regarding this purchase are available in the official SEC disclosure. In the last 90 days, insiders acquired 22,200 shares of company stock valued at $2,215,100 and sold 3,055 shares valued at $353,097. 0.46% of the stock is currently owned by company insiders.

Wall Street Analysts Forecast Growth

ABT has been the topic of a number of research reports. The Goldman Sachs Group cut their price objective on Abbott Laboratories from $140.00 to $121.00 and set a “buy” rating on the stock in a report on Wednesday, April 8th. Sanford C. Bernstein cut their price objective on Abbott Laboratories from $125.00 to $110.00 and set an “outperform” rating on the stock in a report on Friday, April 17th. Mizuho cut their price objective on Abbott Laboratories from $125.00 to $115.00 and set a “neutral” rating on the stock in a report on Friday, April 17th. Wells Fargo & Company cut their price objective on Abbott Laboratories from $122.00 to $109.00 and set an “overweight” rating on the stock in a report on Friday, April 17th. Finally, Argus cut their price objective on Abbott Laboratories from $140.00 to $125.00 and set a “buy” rating on the stock in a report on Tuesday, April 21st. Two research analysts have rated the stock with a Strong Buy rating, nineteen have assigned a Buy rating and five have given a Hold rating to the company. According to MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $119.43.

Abbott Laboratories Company Profile

Abbott Laboratories is a global healthcare company headquartered in Abbott Park, Illinois, that develops, manufactures and markets a broad portfolio of medical products and services. Founded in 1888, Abbott operates through multiple business areas that focus on diagnostics, medical devices, nutritionals and established pharmaceuticals. The company supplies hospitals, clinics, laboratories, retailers and direct-to-consumer channels with products intended to diagnose, treat and manage a wide range of health conditions.

In diagnostics, Abbott provides laboratory and point-of-care testing platforms and assays used to detect infectious diseases, chronic conditions and biomarkers; its Alinity family of instruments and rapid-test solutions are examples of this capability.